Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies

被引：440

作者：

Adamska, Aleksandra ^{[1
]}

Domenichini, Alice ^{[1
]}

Falasca, Marco ^{[1
]}

机构：

[1] Curtin Univ, Metab Signalling Grp, Sch Biomed Sci, Curtin Hlth Innovat Res Inst, Perth, WA 6102, Australia

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2017年 / 18卷 / 07期

关键词：

PDAC; chemotherapy; gemcitabine; Abraxane; FOLFIRINOX; combination therapies; targeted therapies; PHASE-II TRIAL; COOPERATIVE-ONCOLOGY-GROUP; GEMCITABINE-BASED CHEMORADIATION; PACLITAXEL PLUS GEMCITABINE; MTOR INHIBITOR EVEROLIMUS; PLACEBO-CONTROLLED TRIAL; GROWTH-FACTOR RECEPTOR; NEOADJUVANT THERAPY; DOUBLE-BLIND; PREOPERATIVE CHEMORADIATION;

D O I：

10.3390/ijms18071338

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Pancreatic ductal adenocarcinoma (PDAC), which constitutes 90% of pancreatic cancers, is the fourth leading cause of cancer-related deaths in the world. Due to the broad heterogeneity of genetic mutations and dense stromal environment, PDAC belongs to one of the most chemoresistant cancers. Most of the available treatments are palliative, with the objective of relieving disease-related symptoms and prolonging survival. Currently, available therapeutic options are surgery, radiation, chemotherapy, immunotherapy, and use of targeted drugs. However, thus far, therapies targeting cancer-associated molecular pathways have not given satisfactory results; this is due in part to the rapid upregulation of compensatory alternative pathways as well as dense desmoplastic reaction. In this review, we summarize currently available therapies and clinical trials, directed towards a plethora of pathways and components dysregulated during PDAC carcinogenesis. Emerging trends towards targeted therapies as the most promising approach will also be discussed.

引用

页数：43

共 287 条

[81] nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial [J].

Goldstein, David ;

El-Maraghi, Robert Hassan ;

Hammel, Pascal ;

Heinemann, Volker ;

Kunzmann, Volker ;

Sastre, Javier ;

Scheithauer, Werner ;

Siena, Salvatore ;

Tabernero, Josep ;

Teixeira, Luis ;

Tortora, Giampaolo ;

Van Laethem, Jean-Luc ;

Young, Rosemary ;

Penenberg, Darryl Neil ;

Lu, Brian ;

Romano, Alfredo ;

Von Hoff, Daniel D. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2015, 107 (02)

[82] BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer [J].

Goncalves, A. ;

Gilabert, M. ;

Francois, E. ;

Dahan, L. ;

Perrier, H. ;

Lamy, R. ;

Re, D. ;

Largillier, R. ;

Gasmi, M. ;

Tchiknavorian, X. ;

Esterni, B. ;

Genre, D. ;

Moureau-Zabotto, L. ;

Giovannini, M. ;

Seitz, J-F. ;

Delpero, J-R. ;

Turrini, O. ;

Viens, P. ;

Raoul, J-L. .

ANNALS OF ONCOLOGY, 2012, 23 (11) :2799-2805

[83] Expression of MicroRNA-15b and the Glycosyltransferase GCNT3 Correlates with Antitumor Efficacy of Rosemary Diterpenes in Colon and Pancreatic Cancer [J].

Gonzalez-Vallinas, Margarita ;

Molina, Susana ;

Vicente, Gonzalo ;

Zarza, Virginia ;

Martin-Hernandez, Roberto ;

Garcia-Risco, Monica R. ;

Fornari, Tiziana ;

Reglero, Guillermo ;

Ramirez de Molina, Ana .

PLOS ONE, 2014, 9 (06)

[84] Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial [J].

Gourgou-Bourgade, Sophie ;

Bascoul-Mollevi, Caroline ;

Desseigne, Francoise ;

Ychou, Marc ;

Bouche, Olivier ;

Guimbaud, Rosine ;

Becouarn, Yves ;

Adenis, Antoine ;

Raoul, Jean-Luc ;

Boige, Valerie ;

Berille, Jocelyne ;

Conroy, Thierry .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (01) :23-29

[85] Effect of neoadjuvant therapy on local recurrence after resection of pancreatic adenocarcinoma [J].

Greer, Sarah E. ;

Pipas, J. Marc ;

Sutton, John E. ;

Zaki, Bassem I. ;

Tsapakos, Michael ;

Colacchio, Thomas A. ;

Gibson, Jennifer J. ;

Wiener, Daniel C. ;

Ripple, Gregory H. ;

Barth, Richard J., Jr. .

JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2008, 206 (03) :451-457

[86] Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival [J].

Greither, Thomas ;

Grochola, Lukasz F. ;

Udelnow, Andrej ;

Lautenschlaeger, Christine ;

Wuerl, Peter ;

Taubert, Helge .

INTERNATIONAL JOURNAL OF CANCER, 2010, 126 (01) :73-80

[87] Immunotherapy updates in pancreatic cancer: are we there yet? [J].

Gunturu, Krishna Soujanya ;

Rossi, Gabriela R. ;

Saif, Muhammad Wasif .

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2013, 5 (01) :81-89

[88] The Prognostic and Predictive Role of Epidermal Growth Factor Receptor in Surgical Resected Pancreatic Cancer [J].

Guo, Meng ;

Luo, Guopei ;

Liu, Chen ;

Cheng, He ;

Lu, Yu ;

Jin, Kaizhou ;

Liu, Zuqiang ;

Long, Jiang ;

Liu, Liang ;

Xu, Jin ;

Huang, Dan ;

Ni, Quanxing ;

Yu, Xianjun .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (07)

[89] Pancreatic stellate cells enhance stem cell-like phenotypes in pancreatic cancer cells [J].

Hamada, Shin ;

Masamune, Atsushi ;

Takikawa, Tetsuya ;

Suzuki, Noriaki ;

Kikuta, Kazuhiro ;

Hirota, Morihisa ;

Hamada, Hirofumi ;

Kobune, Masayoshi ;

Satoh, Kennichi ;

Shimosegawa, Tooru .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2012, 421 (02) :349-354

[90] Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib The LAP07 Randomized Clinical Trial [J].

Hammel, Pascal ;

Huguet, Florence ;

van Laethem, Jean-Luc ;

Goldstein, David ;

Glimelius, Bengt ;

Artru, Pascal ;

Borbath, Ivan ;

Bouche, Olivier ;

Shannon, Jenny ;

Andre, Thierry ;

Mineur, Laurent ;

Chibaudel, Benoist ;

Bonnetain, Franck ;

Louvet, Christophe .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 315 (17) :1844-1853

← 4 5 6 7 8 9 10 11 12 13 →